glp-1 r retatrutide vs Semaglutide and Tirzepatide: GLP-3 Facts explained Retatrutide Promises Big Weight Loss,

The goal is not simply to become lighter

The inhibitory effect is presumably mediated indirectly through somatostatin secretion, but a direct effect cannot be completely excluded

In vivo drug discovery for increasing incretin-expressing cells identifies DYRK inhibitors that reinforce the enteroendocrine system

The larger sample size and longer duration provide robust evidence of sustained efficacy

Losing 5% to 10% of body weight through diet and exercise reduces the risk of cardiovascular disease, but diet and exercise alone are not always guaranteed to address the issue

At 48 weeks, weight loss was dose-dependent: the 12 mg group achieved approximately 24.2% mean weight loss, which was meaningfully higher than the approximately 15% reported for semaglutide 2.4 mg in the STEP 1 trial and approximately 20-22% for tirzepatide in the SURMOUNT trials